2XMyc-LRRK2-WT Citations (10)
Originally described in: The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular AutophosphorylationJ Biol Chem. 2008 Jun 13;283(24):16906-14. PubMed Journal
Articles Citing 2XMyc-LRRK2-WT
| Articles |
|---|
| A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. Salasova A, Yokota C, Potesil D, Zdrahal Z, Bryja V, Arenas E. Mol Neurodegener. 2017 Jul 11;12(1):54. doi: 10.1186/s13024-017-0193-9. PubMed |
| LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection. Liu W, Liu X, Li Y, Zhao J, Liu Z, Hu Z, Wang Y, Yao Y, Miller AW, Su B, Cookson MR, Li X, Kang Z. J Exp Med. 2017 Oct 2;214(10):3051-3066. doi: 10.1084/jem.20170014. Epub 2017 Aug 18. PubMed |
| A pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. Dhekne HS, Yanatori I, Gomez RC, Tonelli F, Diez F, Schule B, Steger M, Alessi DR, Pfeffer SR. Elife. 2018 Nov 6;7. pii: 40202. doi: 10.7554/eLife.40202. PubMed |
| LRRK2 Regulates CPT1A to Promote beta-Oxidation in HepG2 Cells. Lin CW, Peng YJ, Lin YY, Mersmann HJ, Ding ST. Molecules. 2020 Sep 9;25(18). pii: molecules25184122. doi: 10.3390/molecules25184122. PubMed |
| LRRK2-phosphorylated Rab10 sequesters Myosin Va with RILPL2 during ciliogenesis blockade. Dhekne HS, Yanatori I, Vides EG, Sobu Y, Diez F, Tonelli F, Pfeffer SR. Life Sci Alliance. 2021 Mar 16;4(5). pii: 4/5/e202101050. doi: 10.26508/lsa.202101050. Print 2021 May. PubMed |
| A cell-based GEF assay reveals new substrates for DENN domains and a role for DENND2B in primary ciliogenesis. Kumar R, Francis V, Kulasekaran G, Khan M, Armstrong GAB, McPherson PS. Sci Adv. 2022 Feb 25;8(8):eabk3088. doi: 10.1126/sciadv.abk3088. Epub 2022 Feb 23. PubMed |
| The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. Stormo AED, Shavarebi F, FitzGibbon M, Earley EM, Ahrendt H, Lum LS, Verschueren E, Swaney DL, Skibinski G, Ravisankar A, van Haren J, Davis EJ, Johnson JR, Von Dollen J, Balen C, Porath J, Crosio C, Mirescu C, Iaccarino C, Dauer WT, Nichols RJ, Wittmann T, Cox TC, Finkbeiner S, Krogan NJ, Oakes SA, Hiniker A. J Cell Biol. 2022 Apr 4;221(4). pii: 213061. doi: 10.1083/jcb.202010065. Epub 2022 Mar 10. PubMed |
| Antibody stabilization for thermally accelerated deep immunostaining. Lai HM, Tang Y, Lau ZYH, Campbell RAA, Yau JCN, Chan CCY, Chan DCW, Wong TY, Wong HKT, Yan LYC, Wu WKK, Wong SH, Kwok KW, Wing YK, Lam HHN, Ng HK, Mrsic-Flogel TD, Mok VCT, Chan JYK, Ko H. Nat Methods. 2022 Sep;19(9):1137-1146. doi: 10.1038/s41592-022-01569-1. Epub 2022 Sep 1. PubMed |
| The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis. Zhou ZD, Saw WT, Ho PGH, Zhang ZW, Zeng L, Chang YY, Sun AXY, Ma DR, Wang HY, Zhou L, Lim KL, Tan EK. Cell Mol Life Sci. 2022 Nov 21;79(12):599. doi: 10.1007/s00018-022-04574-x. PubMed |
| Upregulation of LRRK2 following traumatic brain injury does not directly phosphorylate Thr(175) tau. Donison N, Hintermayer M, Subramaniam M, Santandrea E, Volkening K, Strong MJ. Front Cell Neurosci. 2023 Nov 8;17:1272899. doi: 10.3389/fncel.2023.1272899. eCollection 2023. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.